Showing results (271-280 of 287) with videos related to

Sort By:
Pageof 29
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2019
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 studyRobert T Naismith, Jerry S Wolinsky, Annette Wundes, et al.
The Lancet. Neurology|September 22, 2024
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trialsXavier Montalban, Patrick Vermersch, Douglas L Arnold, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b studyGavin Giovannoni, Laura Airas, Riley Bove, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L Hauser, Amit Bar-Or, Giancarlo Comi, et al.
Neurology|June 8, 2023
Polygenicity of Comorbid Depression in Multiple SclerosisKaarina Kowalec, Kathryn C Fitzgerald, Amber Salter, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalban, Stephen L Hauser, Ludwig Kappos, et al.
Neurology|April 6, 2011
Interferon β-1b and glatiramer acetate effects on permanent black hole evolutionM Filippi, M A Rocca, F Camesasca, et al.
Annals of Clinical and Translational Neurology|March 22, 2018
Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS studyDavid H Miller, Fred D Lublin, Maria Pia Sormani, et al.
Annals of Clinical and Translational Neurology|May 8, 2024
Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosisKaarina Kowalec, Arvid Harder, Casandra Dolovich, et al.
European Journal of Neurology|March 16, 2021
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registryHelmut Butzkueven, Tim Spelman, Dana Horakova, et al.
Pageof 29